Sheng Kuo, MD
Nephrology · Bronx, NYNPI 1134317944
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.4%), speaking fees and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Aurinia Pharma U.S., Inc. at 47.0% of the total. Reporting peaked in 2021 at $3,435 and has fallen 94.9% since, to $176 in 2024.
Across 142 payments — averaging $43.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$3K
- AstraZeneca$866
- Vifor Pharma, Inc.$653
- Bayer$336
- Amgen$213
- OPKO Pharmaceuticals, LLC$210
- plus $970 from 12 others
Across 13 payments — averaging $3535.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aurinia Pharma U.S., Inc.$22K
- Vertex$19K
- Humacyte Global, Inc.$6K
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$2,77045%
- Travel & lodging$811%
- Food & beverage$2,84546%
- Education$2785%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 10 | $2,876 |
| AstraZeneca(2 entities) | 31 | $866 |
| Vifor Pharma, Inc. | 33 | $653 |
| Bayer | 14 | $336 |
| Amgen(2 entities) | 8 | $213 |
| OPKO Pharmaceuticals, LLC | 9 | $210 |
| Travere Therapeutics, Inc. | 5 | $209 |
| Otsuka America Pharmaceutical, Inc. | 7 | $194 |
| Fresenius USA Marketing, Inc. | 6 | $127 |
| Mallinckrodt Hospital Products Inc. | 2 | $83 |
| Calliditas Therapeutics US Inc. | 4 | $82 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Johnson & Johnson | 2 | $51 |
| Novartis | 2 | $41 |
| Cumberland Pharmaceuticals, Inc. | 3 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$2,660
How this compares
$6,124 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 293 | $319,244 |
| LokelmaSodium Zirconium Cyclosilicate | 62 | $87,400 |
| JardianceEmpagliflozin | 78 | $75,905 |
| KerendiaFinerenone | 49 | $72,257 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $34,245 |
| Cinacalcet Hcl | 22 | $33,365 |
| RayaldeeCalcifediol | 26 | $22,722 |
| TradjentaLinagliptin | 16 | $21,373 |
| RetacritEpoetin Alfa-Epbx | 14 | $17,354 |
| DapagliflozinDapagliflozin Propanediol | 20 | $13,883 |
| Eplerenone | 115 | $9,109 |
| Mycophenolate Mofetil | 41 | $4,762 |
| Tacrolimus | 21 | $3,764 |
| Potassium Citrate ErPotassium Citrate | 33 | $3,163 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 76 | $2,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $866 | $406,644355 claims |
| BayerKerendia | $336 | $72,25749 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $210 | $22,72226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in Bronx
- Bruce SpinowitzBronx$465K
- Joel NeugartenBronx$248K
- Enver AkalinBronx$101K
- John KangBronx$93K
- Daniel AddankiBronx$54K
- Chaim CharytanBronx$34K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.